A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

A vizsgálat adatai

Ki végzi

Global Coalition for Adaptive Research

Azonosító

NCT03970447EU 2024-511452-40-00

A regiszteradat frissítve

2026. november 2.

Eredeti leírás

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.A teljes eredeti leírásKevesebb

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (*).

Newly Diagnosed Inclusion Criteria:; Age ≥ 18 years; Histologically confirmed Grade IV GBM, inclusive of gliosarcoma (WHO criteria; IDH wild-type by immunohistochemistry [IHC] or sequencing for IDH) established following either a surgical resection or biopsy. An MRI scan with the required imaging sequences performed within 21 days prior to randomization preferably. The post-operative MRI scan performed within 96 hours of surgery or the MRI scan performed for radiation therapy planning may serve as the MRI scan performed during screening if all required imaging sequences were obtained; Karnofsky performance status ≥ 60% performed within a 14-day window prior to randomization; Availability of tumor tissue representative of GBM from definitive surgery or biopsy; Recurrent Inclusion Criteria:; Age ≥ 18 years; Histologically confirmed Grade IV GBM, inclusive of gliosarcoma (WHO criteria; IDH wild-type by immunohistochemistry [IHC] or sequencing for IDH) at first or second recurrence after initial standard, control or experimental therapy that includes at a minimum radiation therapy (RT); Evidence of recurrent disease demonstrated by disease progression using slightly modified Response Assessment in Neuro-Oncology (RANO) criteria; Two scans to confirm progression are required: at least 1 scan at the time of progression and 1 scan prior to the time of progression; Karnofsky performance status ≥ 70% performed within a 14-day window prior to randomization; Availability of tumor tissue representative of GBM from initial definitive surgery and/or, recurrent surgery, if performed; Newly Diagnosed Exclusion Criteria:; Received any prior treatment for glioma including: a. Prior prolifeprospan 20 with carmustine wafer. b. Prior intracerebral, intratumoral, or cerebral spinal fluid (CSF) agent. c. Prior radiation treatment for GBM or lower-grade glioma. d. Prior chemotherapy or immunotherapy for GBM or lower-grade glioma. Receiving additional, concurrent, active therapy for GBM outside of the trial; Extensive leptomeningeal disease; QTc > 470 msec; History of another malignancy in the previous 2 years, with a disease-free interval of < 2 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible; Recurrent Exclusion Criteria:; Early disease progression prior to 3 months (12 weeks) from the completion of RT; More than 2 prior lines for chemotherapy administration. (NOTE: In the 1st line adjuvant setting, combination of temozolomide (TMZ) with an experimental agent, is considered one line of chemotherapy.); Received any prior treatment with lomustine, agents part of any of the experimental arms, or bevacizumab or other vascular endothelial growth factor (VEGF) or VEGF receptor-mediated targeted agent; Any prior treatment with prolifeprospan 20 with carmustine wafer; Any prior treatment with an intracerebral agent; Receiving additional, concurrent, active therapy for GBM outside of the trial; Extensive leptomeningeal disease; QTc > 470 msec; History of another malignancy in the previous 2 years, with a disease-free interval of < 2 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.

ClinicalTrials.gov NCT03970447 · EU CTIS 2024-511452-40-00